Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.03
-0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM EST
10.18
+0.15 (1.50%)
After-hours: Nov 16, 2026, 7:30 PM EST
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $40.01M in the quarter ending September 30, 2026, with 180.53% growth. This brings the company's total for the last twelve months to $40.76M, down -83.48% year-over-year. In the year 2025, Keros Therapeutics had annual revenue of $244.06M with 6,774.96% growth. That makes Keros Therapeutics the 29,432nd largest company in the world by revenue and 3,912th in the United States.
Revenue (ttm)
$40.76M
Revenue Growth
-83.48%
P/S Ratio
4.85
Revenue / Employee
$468,517
Employees
87
Market Cap
196.83M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 244.06M | 240.51M | 6,774.96% |
| Dec 31, 2024 | 3.55M | 3.40M | 2,250.99% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 20.10M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 10.00M | - | - |
| Dec 31, 2018 | 10.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 75.93M |
| AC Immune | 23.75M |
| ProQR Therapeutics | 23.46M |
| Pyxis Oncology | 11.04M |
| Entrada Therapeutics | 3.98M |
| Korro Bio | 1.29M |
| Cartesian Therapeutics | 1.03M |
| Palisade Bio | 500.00K |
KROS News
- 5 hours ago - Keros Therapeutics authorizes additional $5M share repurchase - TheFly
- 6 hours ago - Keros Therapeutics Announces Additional $5 Million Share Repurchase Authorization - GlobeNewsWire
- 15 hours ago - Keros Therapeutics price target raised to $18 from $17 at BofA - TheFly
- 11 days ago - Keros Therapeutics reports Q3 EPS 70c, consensus (86c) - TheFly
- 11 days ago - Keros Therapeutics Earnings release: Q3 2026 - Filings
- 11 days ago - Keros Therapeutics Quarterly report: Q3 2026 - Filings
- 27 days ago - Keros Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 6 weeks ago - Keros Therapeutics to receive $20M development milestone payment from Takeda - TheFly